Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

B7-H3 Trike Enhances Killing of Myeloid Derived Suppressor Cells in Multiple Myeloma

Aimee Merino, Hayden Hamsher, Daniel Mansour, Gregory I. Berk, Martin Felices, Jeffrey S. Miller, MD

Blood (2022) 140 (Supplement 1): 8851–8852.

https://doi.org/10.1182/blood-2022-162566

Published: 2022

Journal Articles

A Novel Dual-Antigen Targeting Approach Enables Off-the-Shelf CAR NK Cells to Effectively Recognize and Eliminate the Heterogenous Population Associated with AML

Zachary Davis, Frank Cichocki, Martin Felices, Hongbo Wang, Peter Hinderlie, Mark Juckett, Joseph Maakaron, Gregory I. Berk, Bryan Hancock, John Goulding, Ryan Bjordahl, Bahram Valamehr, Jeffrey S. Miller, MD

Blood (2022) 140 (Supplement 1): 10288–10289.

https://doi.org/10.1182/blood-2022-168981

Published: 2022

Journal Articles

Inhibiting PIM-1 Is Effective in Vitro and in Vivo against ALL: A Novel Mechanistic and Potentially Clinically Relevant Druggable Target.

Valerie I. Brown, MD, PhD, Cecilia Sheen, Jessica Hulitt, Theresa Ryan, Laura DiNardo, David Barrett, MD, PhD, David T. Teachey, MD, David J. Bearss, PhD, Gregory I. Berk, MD, Stephan A. Grupp, MD, PhD

Blood (2008) 112 (11): 1922.

https://doi.org/10.1182/blood.V112.11.1922.1922

Published: 2008

Journal Articles

A Phase I Study of Talvesta® (Talotrexin) in Relapsed or Refractory Leukemia or Myelodysplastic Syndrome.

Francis Giles, MD, David A. Rizzieri, MD, Solly George, RN, Wendy Stock, MD, Jeannie Fontanilla, BS, Gavin S. Choy, PharmD, Gregory I. Berk, MD

Blood (2006) 108 (11): 1968.

https://doi.org/10.1182/blood.V108.11.1968.1968

Published: 2006

Journal Articles

Phase I Trial of Sphingosomal Vincristine (SV, Marqibo®) and Dexamethasone in Relapsed or Refractory Acute Lymphocytic Leukemia (ALL).

Deborah A. Thomas, MD, Hagop M. Kantarjian, MD, Leonard Heffner, MD, Wendy Stock, MD, Guillermo Garcia-Manero, MD, Stefan Faderl, MD, Alessandra Ferrajoli, MD, Francis Giles, MD, William Wierda, MD, Farhad Ravandi-Kashani, MD, Gavin Choy, PharmD, Gregory I. Berk, MD, Susan O’Brien, MD

Blood (2006) 108 (11): 4539.

https://doi.org/10.1182/blood.V108.11.4539.4539

Published: 2006

NARROW

B7-H3 Trike Enhances Killing of Myeloid Derived Suppressor Cells in Multiple Myeloma

A Novel Dual-Antigen Targeting Approach Enables Off-the-Shelf CAR NK Cells to Effectively Recognize and Eliminate the Heterogenous Population Associated with AML

Inhibiting PIM-1 Is Effective in Vitro and in Vivo against ALL: A Novel Mechanistic and Potentially Clinically Relevant Druggable Target.

A Phase I Study of Talvesta® (Talotrexin) in Relapsed or Refractory Leukemia or Myelodysplastic Syndrome.

Phase I Trial of Sphingosomal Vincristine (SV, Marqibo®) and Dexamethasone in Relapsed or Refractory Acute Lymphocytic Leukemia (ALL).

Email alerts

ASH Publications

American Society of Hematology

B7-H3 Trike Enhances Killing of Myeloid Derived Suppressor Cells in Multiple Myeloma

A Novel Dual-Antigen Targeting Approach Enables Off-the-Shelf CAR NK Cells to Effectively Recognize and Eliminate the Heterogenous Population Associated with AML

Inhibiting PIM-1 Is Effective in Vitro and in Vivo against ALL: A Novel Mechanistic and Potentially Clinically Relevant Druggable Target.

A Phase I Study of Talvesta® (Talotrexin) in Relapsed or Refractory Leukemia or Myelodysplastic Syndrome.

Phase I Trial of Sphingosomal Vincristine (SV, Marqibo®) and Dexamethasone in Relapsed or Refractory Acute Lymphocytic Leukemia (ALL).

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only